News
7h
Fintel on MSNHC Wainwright & Co. Initiates Coverage of TMC the metals (TMC) with Buy RecommendationFintel reports that on May 20, 2025, HC Wainwright & Co. initiated coverage of TMC the metals (NasdaqGS:TMC) with a Buy ...
19h
Fintel on MSNHC Wainwright & Co. Downgrades Prime Medicine (PRME)Fintel reports that on May 20, 2025, HC Wainwright & Co. downgraded their outlook for Prime Medicine (NasdaqGM:PRME) from Buy to Neutral. Analyst Price Forecast Suggests 726.84% Upside As of May 7, ...
About This EventH.C. Wainwright & Co., full‐service investment bank, visits the Nasdaq MarketSite in Times Square.In honor of the occasion, the 3rd Annual BioConnect Conference, John Chambers and ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura ...
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the ...
CytomX Therapeutics (CTMX) stock was upgraded to Buy from Neutral at H.C. Wainwright after promising Phase 1 trial results for its colorectal cancer drug. Read more here.
The latest analyst rating for OptiNose (NASDAQ:OPTN) was provided by HC Wainwright & Co., and OptiNose reiterated their neutral rating. The last downgrade for OptiNose Inc happened on March 21 ...
SAN FRANCISCO, May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect ...
The latest price target for Knightscope (NASDAQ:KSCP) was reported by Ascendiant Capital on April 28, 2025. The analyst firm set a price target for $30.00 expecting KSCP to rise to within 12 ...
Detailed price information for Xenetic Biosciences Inc (XBIO-Q) from The Globe and Mail including charting and trades.
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
Fortress Biotech, Inc. (Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity ...
A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results